Replies to post #139878 on Biotech Values

[genisi]

I was thinking that results from the CO-PILOT study bode well for VRTX' oral combo in the sense of both contain drugs with the same MoA (PI+non-nuke+Riba) and ABT-333 was dosed BID (ABT-072 was dosed QD in PILOT study). Of course both would be inferior to a QD combo with similar SVR.